NCT04524507View on ClinicalTrials.gov

Coronavirus Disease 2019 (COVID-19) Antibody Plasma Research Study in Hospitalized Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

August 27, 2020

Primary Completion Date

January 4, 2021

Study Completion Date

June 4, 2021

Conditions
COVID-19
Interventions
BIOLOGICAL

High-titer Convalescent COVID-19 Plasma (CCP1)

At least two units of CCP transfused 4-24 hours apart on Study Day 0. A third unit may be administered, if available.

BIOLOGICAL

Standard-titer Convalescent COVID-19 plasma (CCP2)

At least two units of CCP transfused 4-24 hours apart on Study Day 0. A third unit may be administered, if available.

Trial Locations (1)

27514

University of North Carolina Health Care, Chapel Hill

All Listed Sponsors
lead

University of North Carolina, Chapel Hill

OTHER

NCT04524507 - Coronavirus Disease 2019 (COVID-19) Antibody Plasma Research Study in Hospitalized Patients | Biotech Hunter | Biotech Hunter